Aarti Drugs Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Net profit of Aarti Drugs declined 12.20% to Rs 55.19 crore in the quarter ended March 2026 as against Rs 62.86 crore during the previous quarter ended March 2025. Sales rose 6.43% to Rs 720.30 crore in the quarter ended March 2026 as against Rs 676.76 crore during the previous quarter ended March 2025.

For the full year,net profit rose 15.91% to Rs 194.92 crore in the year ended March 2026 as against Rs 168.16 crore during the previous year ended March 2025. Sales rose 7.47% to Rs 2565.31 crore in the year ended March 2026 as against Rs 2387.03 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Net profit of Aarti Drugs declined 26.87% to Rs 44.96 crore in the quarter ended March 2026 as against Rs 61.48 crore during the previous quarter ended March 2025. Sales rose 1.40% to Rs 631.68 crore in the quarter ended March 2026 as against Rs 622.96 crore during the previous quarter ended March 2025.

For the full year,net profit rose 7.57% to Rs 169.22 crore in the year ended March 2026 as against Rs 157.31 crore during the previous year ended March 2025. Sales rose 3.99% to Rs 2260.39 crore in the year ended March 2026 as against Rs 2173.65 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 15 May 2026.

With this incorporation, Tripharma Chile SpA becomes a step-down subsidiary of Aarti Drugs. The newly formed entity has been established to market formulation drugs and participate in government tenders as well as the private pharmaceutical market in Chile. The business activities of the new subsidiary are aligned with those of its holding companies.

The cost of subscription stands at 1,000,000 Chilean pesos towards share capital contribution, comprising 1,000,000 shares. The entire share capital of Tripharma Chile SpA will be held by Pinnacle Chile SpA, making it a wholly owned step-down subsidiary of the company.

Aarti Drugs was established in the year 1984 and forms part of the $6 billion Aarti Group of Industries. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates and speciality chemicals and produces formulations with its wholly-owned subsidiary, Pinnacle Life Science.

The company reported a 9.4% increase in consolidated net profit to Rs 40.54 crore on an 8.1% rise in net sales to Rs 601.71 crore in Q3 FY26 as compared with Q3 FY25.

Powered by Capital Market - Live News